AcouBatt raised £1.1m to listen inside batteries

AcouBatt raised £1.1 million in pre-seed funding to put a stethoscope on lithium-ion production. The London startup, spun out of UCL Ventures, will use the round led by Creator Fund with participation from Ada Ventures to move its acoustic diagnostics from lab to factory floor.

The problem it targets is concrete.

During formation, a new cell is charged and discharged for the first time. Today that stage is a black box. Manufacturers have almost no real-time visibility, so cells sit for up to two weeks on conservative time buffers while operators wait blind. The result is a bottleneck that inflates cost, wastes material with up to 30 percent rejection rates, and still lets defects slip through.

AcouBatt listens instead. As electrochemical and mechanical changes happen inside the cell they emit tiny acoustic signals. The company places proprietary acoustic emission sensors on or near the cell during formation and streams that audio together with the cycler’s voltage and current traces. Its AI learns to separate meaningful battery activity from factory background noise, then interprets the signatures as they occur.

That sync is the product. By aligning acoustic events with electrochemical data, the system declares when key formation reactions are actually complete, so the line can drop the buffer and move the batch. AcouBatt says that trims formation time by up to 30 percent without hurting performance. The same signal path flags the earliest acoustic signatures of a developing fault, the kind traditional end-of-line electrical tests miss, and catches process drift before a whole batch is scrapped.

Integration is designed to be non-invasive. Jamie Macfarlane, CEO at Creator Fund, which led the round, said the appeal is that it is not destructive and does not change anything in the manufacturing process but allows producers to understand what is happening inside batteries at speed. For now the hardware lives in the lab at the UK Battery Industrialisation Centre, the UK’s national scale-up facility, where AcouBatt is benchmarking diagnostics against production-relevant cells. Commercial scale products are targeted for next year.

Beyond formation, the company wants the same sensor and models to sit on battery energy storage systems to spot underperforming or failing cells before they trigger safety incidents or unplanned downtime. Over time that extends to EVs and other systems as a through-life health monitor. Co-founder and CEO Dr. Arthur Fordham, whose PhD at UCL’s Electrochemical Innovation Lab under the Faraday Institution’s SafeBatt project underpins the IP, said batteries have been tightly locked in a black box and diagnostics are the next frontier from formation to end of life. Co-founder and Commercial Director Chris Haoxin Xu, who met Fordham through London Business School’s Innovation to Market programme, framed it as a way to cut waste and get safer cells out faster under pressure to scale Western production.

There are limits in the current disclosure. The system is still in pilot at UKBIC, not yet proven across multiple chemistries or form factors at line speed, and AcouBatt has not published false positive rates or how its models handle variable acoustic coupling and factory noise over months of operation. Will Mortimore, business manager at UCL Ventures, which assigned the IP into the company, and Matt Penneycard, co-founding partner at Ada Ventures, both pointed to the waste and safety cost of blind formation as the reason to back the approach.

If the acoustic fingerprint holds up outside the lab, manufacturers gain a control signal they have never had, not a new chemistry but a way to know when to stop waiting.